• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by Metsera Inc.

    2/10/25 9:30:19 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTSR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    Metsera, Inc.

    (Name of Issuer)


    Common Stock, $0.00001 par value

    (Title of Class of Securities)


    59267L107

    (CUSIP Number)


    Mark McDonnell
    ARCH Venture Management, LLC, 8755 W. Higgins Road Suite 1025
    Chicago, IL, 60631
    (773)380-6600

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    02/03/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    59267L107


    1 Name of reporting person

    ARCH Venture Fund XII, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    26,816,808.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    26,816,808.00
    11Aggregate amount beneficially owned by each reporting person

    26,816,808.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    25.5 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    59267L107


    1 Name of reporting person

    ARCH Venture Partners XII, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    26,816,808.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    26,816,808.00
    11Aggregate amount beneficially owned by each reporting person

    26,816,808.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    25.5 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    59267L107


    1 Name of reporting person

    ARCH Venture Partners XII, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    26,816,808.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    26,816,808.00
    11Aggregate amount beneficially owned by each reporting person

    26,816,808.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    25.5 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    59267L107


    1 Name of reporting person

    ARCH Venture Fund XIII, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    26,816,808.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    26,816,808.00
    11Aggregate amount beneficially owned by each reporting person

    26,816,808.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    25.5 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    59267L107


    1 Name of reporting person

    ARCH Venture Partners XIII, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    26,816,808.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    26,816,808.00
    11Aggregate amount beneficially owned by each reporting person

    26,816,808.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    25.5 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    59267L107


    1 Name of reporting person

    ARCH Venture Partners XIII, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    26,816,808.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    26,816,808.00
    11Aggregate amount beneficially owned by each reporting person

    26,816,808.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    25.5 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    59267L107


    1 Name of reporting person

    Kristina Burow
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    12,412.00
    8Shared Voting Power

    26,816,808.00
    9Sole Dispositive Power

    12,412.00
    10Shared Dispositive Power

    26,816,808.00
    11Aggregate amount beneficially owned by each reporting person

    26,829,220.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    25.5 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    59267L107


    1 Name of reporting person

    Keith Crandell
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    26,816,808.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    26,816,808.00
    11Aggregate amount beneficially owned by each reporting person

    26,816,808.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    25.5 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    59267L107


    1 Name of reporting person

    Steven Gillis
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    26,816,808.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    26,816,808.00
    11Aggregate amount beneficially owned by each reporting person

    26,816,808.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    25.5 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    59267L107


    1 Name of reporting person

    Robert Nelsen
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    26,816,808.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    26,816,808.00
    11Aggregate amount beneficially owned by each reporting person

    26,816,808.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    25.5 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    59267L107


    1 Name of reporting person

    Paul Berns
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    976,178.00
    8Shared Voting Power

    8,313,680.00
    9Sole Dispositive Power

    976,178.00
    10Shared Dispositive Power

    8,313,680.00
    11Aggregate amount beneficially owned by each reporting person

    9,289,858.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.8 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.00001 par value
    (b)Name of Issuer:

    Metsera, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    3 World Trade Center, 175 Greenwich Street, New York, NEW YORK , 10007.
    Item 1 Comment:
    This statement relates to the Common Stock, $0.00001 par value per share (the "Common Stock"), of Metsera, Inc. (the "Issuer") having its principal executive office at 3 World Trade Center, 175 Greenwich Street, New York, NY, 10007 USA.
    Item 2.Identity and Background
    (a)
    (a) This statement is being filed by (1) ARCH Venture Fund XII, L.P. ("AVF XII"), (2) ARCH Venture Partners XII, L.P. ("AVP XII LP") which is the sole general partner of AVF XII, (3) ARCH Venture Partners XII, LLC ("AVP XII LLC") which is the sole general partner of AVP XII LP, (4) ARCH Venture Fund XIII, L.P. ("AVF XIII"), (5) ARCH Venture Partners XIII, L.P. ("AVP XIII LP") which is the sole general partner of AVF XIII, (6) ARCH Venture Partners XIII, LLC ("AVP XIII LLC") which is the sole general partner of AVP XIII LP, (7) Keith Crandell ("Crandell"), (8) Robert Nelsen ("Nelsen"), (9) Kristina Burow ("Burow"), (10) Steven Gillis ("Gillis"), and (11) Paul Berns ("Berns"). Gillis, together with Nelsen, Crandell and Burow, are referred to collectively the "AVP XII Investment Committee Members"). Berns, together with Nelsen, Crandell, Gillis and Burow are referred to collectively the "AVP XIII Investment Committee Members". Each of the individuals and entities above shall be referred to herein as a "Reporting Person" and collectively as the "Reporting Persons".
    (b)
    The business address of each of the Reporting Persons is 8755 West Higgins Road, Suite 1025, Chicago, IL, 60631.
    (c)
    The principal business of AVP XII LP is to act as the general partner of AVF XII, and the principal business of AVP XIII is to act as the general partner of AVF XIII. The principal business of AVP XII LLC is to act as the general partner of AVP XII LP, and the principal business of AVP XIII LLC is to act as the general partner of AVP XIII LP. AVP XII Investment Committee Members and AVP XIII Investment Committee Members act as investment committee members of AVP XII LLC and AVP XIII LLC, respectively, and as managing directors or investment committee members of a number of affiliated partnerships with similar businesses.
    (d)
    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding.
    (e)
    During the five years prior to the date hereof, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.
    (f)
    Each of AVF XII, AVP XII LP, AVF XIII and AVP XIII LP, are limited partnerships organized under the laws of the State of Delaware. Each of AVP XII LLC and AVP XIII LLC is a limited liability company organized under the laws of the State of Delaware. Each AVP XIII Committee Member is a US citizen.
    Item 3.Source and Amount of Funds or Other Consideration
     
    On August 26, 2024, AVF XIII purchased 6,383,731 shares of Series A Preferred Stock of the Issuer at a purchase price of $7.0492 per share. The number of shares reflects a 2.349723 to 1 reverse stock split effective immediately prior to the closing of the initial public offering of the Issuer ("IPO"). Each of the shares of Series A Preferred Stock converted into shares of Common Stock at the closing of the Issuer's IPO. On November 12, 2024, each of AVF XII and AVF XIII purchased 1,139,951 shares of Series B Preferred Stock of the Issuer at a purchase price of $11.8426 per share. The number of shares reflects a 2.349723 to 1 reverse stock split effective immediately prior to the closing of the IPO. Each of the shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's IPO. On February 3, 2025, AVF XII purchased 1,432,224 shares of Common Stock and AVF XIII purchased 789,998 shares of Common Stock, both at a purchase price of $18.00 per share, from the underwriters of the Issuer's IPO. The working capital of AVF XII or AVF XIII, as applicable, was the source of the funds for the purchases. No part of the purchase price paid by AVF XII or AVF XIII, as applicable, was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the shares of Common Stock described above. The total amount paid by for securities purchased in the above-listed transactions is as follows: AVF XII: $39,280,029.84 AVF XIII: $72,719,961.84
    Item 4.Purpose of Transaction
     
    AVF XII, AVF XIII and the other Reporting Persons acquired the Common Stock for investment purposes. Depending on market conditions, the continuing evaluation of the business and prospects of the Issuer and other factors, AVF XII, AVF XIII and other Reporting Persons may dispose of or acquire additional shares of Common Stock of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in, the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D.
    Item 5.Interest in Securities of the Issuer
    (a)
    Amount beneficially owned: AVF XII is the record owner of 18,503,128 shares of Common Stock ("AVF XII Record Shares"). AVP XII LP, as the sole general partner of AVF XII LP, may be deemed to beneficially own the AVF XII Record Shares. AVP XII LLC, as the sole general partner of AVP XII LP, may be deemed to beneficially own the AVF XII Record Shares. AVF XIII is the record holder of 8,313,680 shares of Common Stock ("AVF XIII Record Shares"). AVP XIII LP, as the sole general partner of AVF XIII LP, may be deemed to beneficially own the AVF XIII Record Shares. AVP XIII LLC, as the sole general partner of AVF XIII LP, may be deemed to beneficially own the AVF XIII Record Shares. By virtue of their relationship as affiliated entities who have overlapping general partners and investment committee members, each of the AVP XII Investment Committee Members and direct and indirect general partners of AVF XII may be deemed to share the power to direct AVF XII Record Shares, and each of the AVP XIII Committee Members and direct and indirect general partners of AVF XIII may be deemed to share the power to direct AVF XIII Record Shares (collectively the "Record Shares"). Berns is also the record owner of 957,559 shares of common stock of the Issuer ("Berns Stock") and is the holder of options to purchase 223,430 shares of common stock, of which 18,619 are exercisable now and within the next 60 days. Burow is the holder of options to purchase 148,953 shares of common stock, of which 12,412 are exercisable now and within the next 60 days. Each Reporting Person disclaims beneficial ownership of the Record Shares except for the shares, if any, held of record by such Reporting Person. The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person (other than Berns and Burow) is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based on the 105,326,848 shares outstanding after underwriters allotment which was exercised (as confirmed by the Issuer). The Berns Stock is included in percentage of shares reported by Berns. Vested options are also included in the shares reported for Berns and Burow, respectively.
    (b)
    Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets. (ii) shared power to vote or to direct the vote: See line 8 of cover sheets. (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets. (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.
    (c)
    Except as set forth above, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days.
    (d)
    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, shares beneficially owned by any of the Reporting Persons.
    (e)
    Not applicable
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    AVF XII and AVF XIII are parties to that certain Second Amended and Restated Investors' Rights Agreement, dated November 12, 2024 (the "Investor Rights Agreement"), which is attached as Exhibit 10.12 to the Issuer's Form S-1/A filed on January 27, 2025. Effective as of the closing of the Issuer's IPO, the covenants relating to delivery of financial statements and inspection rights set forth in Section 3 were terminated and rights of first offer were terminated. Pursuant to the Investor Rights Agreement, AVF XII and AVF XIII have certain registration rights with respect to their Common Stock. Specifically, the Issuer has granted demand, piggyback and Form S-3 registration rights, which will terminate upon the earlier of (i) with respect to each stockholder, such date on which all registrable shares held by such stockholder may immediately be sold during any three-month period pursuant to Rule 144 of the Securities Act of 1933, as amended, (ii) the occurrence of a deemed liquidation event, as defined in the Issuer's amended and restated certificate of incorporation, as currently in effect, and (iii) the fifth anniversary of the IPO. The foregoing description of the Investor Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement filed as an exhibit to this Schedule 13D and is incorporated herein by reference. AVF XII, AVF XIII, Burow and Berns have entered into lock-up agreements with the underwriters of the Issuer's IPO pursuant to which AVF XII, AVF XIII, Burow and Berns have generally agreed, subject to certain exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock for a period of 180 days after February 3, 2025, except with the prior written consent of BofA Securities , Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Cantor. The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, the form of which is filed as an exhibit to this Schedule 13D and is incorporated herein by reference.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 1- Agreement of Joint Filing Exhibit 2- Agreement of Joint Filing Exhibit 3- Seconded Amended and Restated Investors' Rights Agreement, dated November 12, 2024, as amended, by and among the Issuer and certain of its stockholders (incorporated by reference to Exhibit 10.12 to the Issuer's Registration Statement on Form S-1/A, as filed with the Securities and Exchange Commission on January 27, 2025). https://www.sec.gov/Archives/edgar/data/2040807/000119312525004504/d900229dex1011.htm Exhibit 4- Form of Lock-Up Agreement (incorporated by reference to Exhibit A to the Form of Underwriting Agreement filed as Exhibit 1.1 to the Issuer's Registration Statement on Form S-1/A as filed with the Securities and Exchange Commission on January 27, 2025). https://www.sec.gov/Archives/edgar/data/2040807/000119312525012756/d900229dex11.htm

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    ARCH Venture Fund XII, L.P.
     
    Signature:ARCH Venture Partners XII, L.P.
    Name/Title:its General Partner
    Date:02/10/2025
     
    Signature:ARCH Venture Partners XII, LLC
    Name/Title:its General Partner
    Date:02/10/2025
     
    Signature:/s/ Mark McDonnell
    Name/Title:** Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director
    Date:02/10/2025
     
    ARCH Venture Partners XII, L.P.
     
    Signature:ARCH Venture Partners XII, LLC
    Name/Title:its General Partner
    Date:02/10/2025
     
    Signature:/s/ Mark McDonnell
    Name/Title:** Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director
    Date:02/10/2025
     
    ARCH Venture Partners XII, LLC
     
    Signature:/s/ Mark McDonnell
    Name/Title:** Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director
    Date:02/10/2025
     
    ARCH Venture Fund XIII, L.P.
     
    Signature:ARCH Venture Partners XIII, L.P.
    Name/Title:its General Partner
    Date:02/10/2025
     
    Signature:ARCH Venture Partners XIII, LLC
    Name/Title:its General Partner
    Date:02/10/2025
     
    Signature:/s/ Mark McDonnell
    Name/Title:** Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
    Date:02/10/2025
     
    ARCH Venture Partners XIII, L.P.
     
    Signature:ARCH Venture Partners XIII, LLC
    Name/Title:its General Partner
    Date:02/10/2025
     
    Signature:/s/ Mark McDonnell
    Name/Title:** Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
    Date:02/10/2025
     
    ARCH Venture Partners XIII, LLC
     
    Signature:/s/ Mark McDonnell
    Name/Title:** Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
    Date:02/10/2025
     
    Kristina Burow
     
    Signature:/s/ Mark McDonnell
    Name/Title:** Mark McDonnell, as Attorney-in-Fact for Kristina Burow
    Date:02/10/2025
     
    Keith Crandell
     
    Signature:/s/ Mark McDonnell
    Name/Title:** Mark McDonnell, as Attorney-in-Fact for Keith Crandell
    Date:02/10/2025
     
    Steven Gillis
     
    Signature:/s/ Mark McDonnell
    Name/Title:** Mark McDonnell, as Attorney-in-Fact for Steven Gillis
    Date:02/10/2025
     
    Robert Nelsen
     
    Signature:/s/ Mark McDonnell
    Name/Title:** Mark McDonnell, as Attorney-in-Fact for Robert Nelsen
    Date:02/10/2025
     
    Paul Berns
     
    Signature:/s/ Mark McDonnell
    Name/Title:** Mark McDonnell, as Attorney-in-Fact for Paul Berns
    Date:02/10/2025
    Comments accompanying signature:
    ** This Schedule 13D was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24.4 to the Form 3 relating to the beneficial ownership of shares of Metsera, Inc. by the Reporting Persons filed with the Securities Exchange Commission on January 31, 2025 and incorporated herein in its entirety by reference.
    Get the next $MTSR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTSR

    DatePrice TargetRatingAnalyst
    2/25/2025$56.00Buy
    Guggenheim
    2/25/2025$38.00Buy
    BofA Securities
    2/25/2025Outperform
    Evercore ISI
    More analyst ratings

    $MTSR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

      MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a monotherapy and co-administered with MET-097i, with five-week monotherapy data expected in Q2 2025MET-097o, an oral formulation of MET-097i, has been accelerated and alternate oral candidate MET-224o is on track, with four-week data for selected lead expected in late 2025 $588 million cash and cash equivalents support runway into 2027 NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical compa

      5/12/25 7:00:11 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metsera to Present at Bank of America 2025 Global Healthcare Conference

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company"), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the Bank of America 2025 Global Healthcare Conference on Wednesday, May 14 at 2:20 - 2:35 P.M. PDT (5:20 – 5:35 P.M. EDT). A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines

      5/8/25 4:01:51 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

      MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and late 2025 on track for MET-233i, an ultra-long acting amylin analog currently in Phase 1 Oral formulation optimization study on track to support initiation of clinical trials for MET-224o and MET097o, with MET-224o data expected in late 2025 Completed IPO with gross proceeds of approximately $316.2 million, extending runway into 2027 NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medici

      3/26/25 7:00:37 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Metsera with a new price target

      Guggenheim initiated coverage of Metsera with a rating of Buy and set a new price target of $56.00

      2/25/25 7:57:00 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Metsera with a new price target

      BofA Securities initiated coverage of Metsera with a rating of Buy and set a new price target of $38.00

      2/25/25 7:56:39 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI initiated coverage on Metsera

      Evercore ISI initiated coverage of Metsera with a rating of Outperform

      2/25/25 7:56:13 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Metsera Inc.

      SCHEDULE 13G/A - Metsera, Inc. (0002040807) (Subject)

      5/12/25 10:36:17 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Metsera Inc.

      10-Q - Metsera, Inc. (0002040807) (Filer)

      5/12/25 7:30:23 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metsera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Metsera, Inc. (0002040807) (Filer)

      5/12/25 7:30:14 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Pinto Joshua

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:42:42 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Executive Chairman Meanwell Clive

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:40:27 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Burow Kristina

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:39:32 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Burow Kristina converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:15:35 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berns Paul L bought $14,219,964 worth of shares (789,998 units at $18.00) and converted options into 7,523,682 shares (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:04:05 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Arch Venture Partners Xii, Llc converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:01:33 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care